Starling Oncology expects $650M-$660M revenue and $4M-$6M adjusted EBITDA in 2026 while targeting 100% capitated revenue growth in 2027 (NASDAQ:STLN)
Starling Oncology (STLN) reported Q3 2026 revenue of $169.8M, up 24% YoY, and adjusted EBITDA of $3.4M. The company expects 2026 revenue of $650M-$660M and adjusted EBITDA of $4M-$6M, targeting 100% capitated revenue growth in 2027, according to management.
How this was made
The 30-second read
Why it matters
The new guidance provides a fresh data point for valuation models and may shift short-term sentiment.
Market read
The article offers primary earnings guidance for a listed biotech, presenting a medium‑term trading opportunity.
What to watch
Potential regulatory delays or clinical trial setbacks could impair the projected growth.
Background
Starling Oncology (NASDAQ:STLN) released its Q3 2026 earnings call highlights and forward guidance.
Ticker impact
Starling Oncology disclosed its 2026 revenue guidance of $650M-$660M and adjusted EBITDA of $4M-$6M, plus a 100% revenue growth target for 2027.
potential upside as investors price in higher future revenue and profitability
The disclosed numbers are new and materially higher than prior guidance, indicating improved outlook.
Market effects
Biotech sector may see modest uplift as a small-cap oncology firm signals strong growth.
U.S. biotech investors may adjust exposure to early-stage oncology pipelines.
Limited to investors tracking small-cap biotech earnings.
Counterpoint
Guidance may be overly optimistic given the company's early-stage pipeline; execution risk could lead to disappointment.
Key entities
- companyStarling Oncology
Biotech firm focused on oncology therapeutics.
- executiveDaniel Virnich
CEO & Executive Director of Starling Oncology.

